Tivozanib approved in Europe for advanced kidney cancer
Tivozanib (Fotivda) has been approved by the European Commission (EC) [...]
Mixed results for nivolumab/ipilimumab combination in advanced kidney cancer
The results from the recent phase III CheckMate-214 clinical trial [...]
New immuno-oncology treatment to be tested in solid tumours
A new immuno-oncology treatment made by British company, Biotecnol, is about to [...]
Initiation of phase 2 clinical trial of glutaminase inhibitor plus everolimus for renal cell carcinoma
Calithera Biosciences, an American pharmaceutical company focused on developing drugs [...]
Current treatment of advanced papillary renal cell carcinoma
Despite significant improvements in the treatment outcomes of clear cell [...]
Recommendations for the management of rare kidney cancers
Patients diagnosed with a rare kidney cancer are often treated [...]
Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer
A retrospective study conducted by researchers in the Czech Republic [...]
Initiation of a phase III trial of immunotherapy plus targeted therapy combinations versus sunitinib
Exelixis and Bristol-Myers Squibb have announced that they have initiated [...]
Cabozantinib recommended by NICE for second-line treatment of advanced kidney cancer
Today, the National Institute for Health and Care Excellence (NICE), [...]
Alternative scheduling of sunitinib and new treatment for kidney cancer: ASCO 2017 update
The following video from Practice Update is an interview with [...]
